权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

In vitro and in vivo characterization of CB1 allosteric modulators

CB1变构调节剂的体外和体内表征

基本信息

批准号：
10431876
负责人：
Thomas F Gamage
金额：
$ 0.9万
依托单位：
RESEARCH TRIANGLE INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-15 至 2023-08-11
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10431876
关键词：
2-arachidonylglycerol Affect Affinity Agonist Antibodies Attenuated Award Behavior Behavioral Behavioral Assay Behavioral Model Binding Biological Biological Assay Budgets CNR1 gene CNR2 gene Cannabinoids Cells Chemicals Clinical Clinical Data Complex Coupling Data Development Disease Dronabinol Drug Addiction Drug Targeting Drug abuse Educational workshop Endocannabinoids Enhancers Exhibits Feeling suicidal Funding GTP Binding GTP-Binding Proteins Goals In Vitro K-Series Research Career Programs Laboratories Learning Ligand Binding Ligands Mental Depression Mentors Metabolic syndrome Modeling Modification Molecular Molecular Biology Molecular Conformation Mus Neuraxis New England Obesity Opioid Pain Parents Pharmaceutical Preparations Pharmacology Pharmacology Study Pharmacotherapy Physiological Pre-Clinical Model Principal Investigator Receptor Signaling Reporting Research SR141716 Self Administration Signal Pathway Signal Transduction Signaling Protein Site Structure Structure-Activity Relationship Techniques Testing Therapeutic Training addiction analog anandamide antagonist antagonist G base cannabinoid receptor career development clinically relevant experimental study improved in vivo induced hypothermia novel opioid abuse opioid withdrawal pre-clinical programs radioligand receptor response responsible research conduct rimonabant scaffold side effect small molecule stoichiometry success synthetic cannabinoid targeted treatment theories therapeutic target vector

项目摘要

The cannabinoid type-1 (CB1) receptor is a promising pharmacotherapeutic target for many diseases as evidenced by a large body of preclinical and clinical data showing efficacy treating drug dependence/addiction, pain, obesity/metabolic syndrome, and others. Unfortunately drugs developed that target the CB1 receptor either directly or indirectly have had limited success, i.e. dronabinol produces undesired psychoactivity, rimonabant produces depression/suicidal ideation, and PF-04457845 did not demonstrate efficacy. Important considerations in the therapeutic vs. nontherapeutic effects of CB1 activation are the various signaling pathways that contribute to either of these. Allosteric modulation provides an additional vector through which the CB1 receptor can be manipulated for therapeutic gain. This study proposes to 1) examine novel structural analogs of established CB1 allosteric modulators for their ability to alter orthosteric ligand binding, function, and signaling bias; 2) characterize G protein subtype-dependent coupling by orthosteric and allosteric ligands in N18TG2 cells which provide physiologically relevant receptor/G protein stoichiometry; and 3) assess the effects of CB1 allosteric modulators in assays of cannabinoid activity, opioid withdrawal and self-administration for determination of efficacy in therapeutically relevant models. My goals for this career development award are to build on my laboratory’s capabilities and prepare for independence as a principal investigator in the behavioral and molecular pharmacology of drug abuse. My laboratory currently has the capabilities to carry out the proposed studies but I require additional training in molecular pharmacology to learn G protein antibody capture scintillation proximity assay to complete Aim 2 which I will learn in Dr. Allyn Howlett’s laboratory. I will also learn complementary techniques in molecular biology in a workshop from New England BioLabs. I will also benefit from guidance in receptor theory, application of allosteric models and quantification of signaling bias which I will receive from my co-mentor Dr. Terry Kenakin. I also require training in self-administration for Aim 3 experiments which I will learn in Dr. Jenny Wiley’s laboratory. In addition to technical training, I require career development in order prepare for research independence. Under this award I will receive training in grantsmanship, laboratory management, budget management, and responsible conduct of research. These career development activities will include one-on-one training with co-mentors as well as workshops to provide me with necessary training to successfully compete for R01 funding and develop a highly productive and efficient independent research program.

大麻素1型（CB1）受体是一种很有前途的药物治疗靶点